Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Noteableon Sep 01, 2024 4:18pm
106 Views
Post# 36204808

RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024

RE:RE:RE:RE:Big pharma is set to keep signing bigger deals in 2024Big Pharma has been listening and has restructured their in-house R&D corporate organizations in advance of impending accelerated deal-making and M&A initiatives.

August 08, 2024 - WSJ - Big Pharma Cuts R&D, Sending Shudders Through Industry

For pharma companies, acquiring a biotech (through M&A process) can be a more cost-effective way to access innovative therapies without the extensive time and expense required to develop new drugs from scratch. 

From the cancer drug Keytruda to the autoimmune disease medication Humira, many of today’s top-selling drugs trace their success to M&As that accelerated their research, development, and market entry.

As pharma companies actively seek to expand their pipelines, biotechs that align with their priorities become increasingly attractive targets or strategic partners. Even as dealmaking becomes more selective, the collaboration between pharma and biotech remains crucial for bringing new, life-saving therapies to patients."




<< Previous
Bullboard Posts
Next >>